Virax Biolabs Group Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Stockholder's Equity - Additional Information (Details)

Stockholder's Equity - Additional Information (Details)					12 Months Ended
Stockholder's Equity - Additional Information (Details)	Nov. 30, 2021 USD ($)	Feb. 26, 2021 USD ($) $ / shares shares	Nov. 13, 2020 USD ($) shares	Apr. 21, 2020 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) Vote $ / shares shares	Mar. 18, 2022 shares	Dec. 13, 2021 USD ($)	Sep. 02, 2021 shares	Jun. 25, 2021 shares	Jun. 24, 2021 shares	Apr. 30, 2021 shares	Mar. 31, 2021 USD ($) shares	Apr. 30, 2020 shares	Apr. 01, 2020 USD ($)
Disclosure of classes of share capital [line items]
Authorized share capital \| $					$ 50,000
Number of shares issued								102,952,766	3,367,409	19,111,119	80,000,000
Number of shares outstanding								102,952,766					20
Related party transaction payable \| $					$ 126,183							$ 371,051
Conversion of class B ordinary shares into class A ordinary shares						83,000
Virax Biolabs Pte. Limited
Disclosure of classes of share capital [line items]
Number of shares issued		581,083										621,795
Issued capital \| $		$ 50,000
Share price per share \| $ / shares		$ 0.09
Related party transaction payable \| $												$ 604,890
Former non-executive Director \| SingaporeCo
Disclosure of classes of share capital [line items]
Number of shares issued			25,717
Compensation award \| $			$ 25,000
Class A Ordinary Shares
Disclosure of classes of share capital [line items]
Number of shares authorised					492,000,000
Par value per share \| $ / shares					$ 0.0001
Number of votes entitled \| Vote					1
Number of shares issued					3,032,792							2,231,083
Number of shares outstanding					3,032,792							2,231,083
Class A Ordinary Shares \| HKCo
Disclosure of classes of share capital [line items]
Number of shares issued				374,062
Share price per share \| $ / shares				$ 1.09
Consideration paid (received) \| $				$ 353,216
Owing amount \| $														$ 54,497
Class A Ordinary Shares \| Virax Biolabs Limited
Disclosure of classes of share capital [line items]
Number of shares issued				353,216								7,547
Subscriptions receivable \| $				$ 54,497
Surrender amount due \| $	$ 54,497
Treasury shares \| $	$ 50,000
Class A Ordinary Shares \| Investor
Disclosure of classes of share capital [line items]
Treasury shares \| $							$ 50,000
Class A Ordinary Shares \| Virax Cayman
Disclosure of classes of share capital [line items]
Shares issued for settlement of related party payable, shares					172,532
Number of shares issued					238,906
Issued capital \| $					$ 519,613
Related party transaction payable \| $					452,861
Issue of convertible instruments \| $					$ 37,735
Conversion of convertible debt					100,000
Class A Ordinary Shares \| Virax Cayman \| Services
Disclosure of classes of share capital [line items]
Number of shares issued					319,536
Issued capital \| $					$ 265,686
Class B Ordinary Shares
Disclosure of classes of share capital [line items]
Number of shares authorised					8,000,000
Par value per share \| $ / shares					$ 0.0001
Number of votes entitled \| Vote					10
Ordinary shares conversion basis					one to one basis
Number of shares issued					6,943,759							6,999,939
Number of shares outstanding					6,943,759							6,999,939
Class B Ordinary Shares \| Virax Biolabs Limited
Disclosure of classes of share capital [line items]
Number of shares issued												6,577,166
Class B Ordinary Shares \| Virax Cayman \| Services
Disclosure of classes of share capital [line items]
Number of shares issued					26,820
Issued capital \| $					$ 24,678